Hydroxychloroquine before prostate removal for resectable localized prostate cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a randomized, double-blind, placebo-controlled window-of-opportunity trial giving oral hydroxychloroquine (or placebo) to men with resectable localized prostate cancer prior to radical prostatectomy. Participants take daily hydroxychloroquine sulfate 400 mg or placebo in the pre- and perioperative period, and prostate tumor and normal tissue are collected at surgery. The study measures autophagy markers (including p62, LC3-II, and NBR1), hydroxychloroquine concentrations in tissue and plasma, and performs tumor genomic analysis to correlate molecular features with response. Safety and tolerability in the surgical setting are monitored closely.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* All patients must have pathological confirmation of adenocarcinoma of the prostate Gleason score 6 (grade Group 1) or greater.
* Patients must have resectable prostate cancer as defined by the AJCC (American Joint Committee on Cancer) TNM system and have planned radical prostatectomy.
* Patients must have sufficient tissue from the initial diagnostic prostate biopsy, as determined by the study pathologist, to perform the required study analyses without exhausting the tissue required for clinical purposes
* Age \>18 years
* Adequate hematopoietic, hepatic and renal function documented prior to study entry to include: Hb. \> 10g/dL, WBC \> 3500/mm3, ANC \> 1500/mm3 and platelets \> 100,000/mm3; hepatic transaminases (AST or ALT) ≤ 2.0 times the upper limits of normal, total bilirubin ≤ 1.5 times the upper limits of normal, estimated creatinine clearance ≥ 60 mL/min or eGFR \> 60 mL/min/1.73 m2 and normal serum cations (K+/Mg2+/Ca2+)
* All patients must be medically fit candidates for radical prostatectomy.
* A patient with any retinopathy will only be enrolled into the study with the approval of a board-certified ophthalmologist
* All patients must give informed consent indicating they are aware of the investigational nature of this study treatment prior to any study procedures being performed.

Exclusion Criteria:

* Patients may not have received radiation therapy for their prostate cancer.
* Patients may not have received chemotherapy for their prostate cancer.
* Patients with gastrointestinal abnormalities including: inability to take oral medication, requirement for intravenous alimentation, or prior major surgery or diseases which may cause malabsorption (e.g. bowel resection, ischemic bowel, Crohns or Ulcerative colitis)
* A serious uncontrolled medical disorder or active infection which would impair their ability to receive study treatment will be excluded.
* Patients with significant cardiac disease: including uncontrolled high blood pressure, unstable angina, congestive heart failure, myocardial infarction within the previous 3 months, or serious cardiac arrhythmias, including a QT interval corrected for heart rate using the Fridericia formula of ≥ 450 ms, or history of Torsade de pointes will be excluded.
* Dementia or significantly altered mental status that would prohibit the understanding or rendering of informed consent and compliance with the requirements of this protocol will be excluded.
* Patients receiving any disease-modifying anti-rheumatic drugs (DMARDs) will be excluded.
* Patients with known or a history of G6PD deficiency will be excluded. Eligible patients will be based on clinician-investigator assessment, that the patient is not at an increased risk for G6PD deficiency (assessment should include information regarding self-reported race/ancestry), OR the patient has a negative screening test for G6PD deficiency.
* Patients taking other commercially available medications which may theoretically either stimulate or inhibit autophagy (calcitriol and chloroquine) will be excluded.
* Patients chronically taking drugs known to cause torsades de pointes will be excluded unless those agents can be discontinued for a period \> 6 times their half-life before study enrollment
* Patients with poorly controlled diabetes mellitus will be excluded.
* Patients with a history of epilepsy will be excluded.
* Patients with a history of porphyria will be excluded

Where it's running

• Dartmouth-Hitchcock Medical Center
  Lebanon, New Hampshire, United States Recruiting

Study contacts

• Principal investigator: Lionel Lewis, MB BCh., MD — Dartmouth-Hitchcock Medical Center
• Study coordinator: Bridget M Labrie
• Email: bridget.m.labrie@hitchcock.org
• Phone: 16036506227

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• HOBSCOTCH for Young Adults with Epilepsy

  This study tests a nine-week home-based program to help young adults (18-29) with epilepsy improve thinking, memory, and quality of life, and also tests a version adapted for youths (13-17) with a parent to see if it helps their thinking, memory, and stress levels for families.

  Recruiting Dartmouth-Hitchcock Medical Center · Lebanon, New Hampshire · NCT07735715

• Remotely Delivered Physical Activity Pathways for Breast Cancer Survivors

  This study tests whether breast cancer survivors who are less active at 6 weeks can be randomized to continue the standard activity program or move to a more intensive step-up program to see if retention and engagement improve.

  Recruiting Dartmouth-Hitchcock Medical Center · Lebanon, New Hampshire · NCT07706556

• Telehealth CBT for insomnia tailored to ulcerative colitis

  This pilot will test whether telehealth cognitive behavioral therapy for insomnia, adapted for adults with ulcerative colitis, can improve sleep and is acceptable to patients.

  Recruiting Dartmouth-Hitchcock Medical Center · Lebanon, New Hampshire · NCT07428629

• Trauma‑Focused Cognitive Behavioral Therapy adapted for autistic children and teens (pilot implementation)

  This pilot will try TF‑CBT adapted for autistic children and teens with trauma-related symptoms to see if community mental health clinicians can deliver it and families find it acceptable.

  Recruiting Dartmouth-Hitchcock Medical Center · Lebanon, New Hampshire · NCT07420478

• Nerve-labeling dye to help protect major nerves during surgery

  This study tests LGW16-03, a dye given by IV before open-field orthopedic surgery to see if it is safe and if it improves nerve visualization for patients undergoing procedures with a major nerve.

  Recruiting Phase 1 Dartmouth-Hitchcock Medical Center · Lebanon, New Hampshire · NCT07385430

• Hyperbaric oxygen for chronic radiation cystitis

  This project will try hyperbaric oxygen therapy in adults with moderate to severe radiation cystitis to see if symptoms improve and urine inflammatory markers change.

  Recruiting Dartmouth-Hitchcock Medical Center · Lebanon, New Hampshire · NCT07368647

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.